Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2)
Spira, A. Zhou, X. L. Liao, L. Yu, E. Chen, L. Lau, A. Wang, Y. Gnanasakthy, A. Hamadani, M.
Spira, A.
Zhou, X. L.
Liao, L.
Yu, E.
Chen, L.
Lau, A.
Wang, Y.
Gnanasakthy, A.
Hamadani, M.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Spira A, Zhou XL, Liao L, Yu E, Chen L, Lau A, et al. Health-Related Quality of Life and Tolerability in Patients With/Without Skin Toxicity During Loncastuximab Tesirine Treatment in a Phase 2 Clinical Trial (LOTIS-2). Clinical Lymphoma Myeloma & Leukemia. 2022 Oct;22:S371-S2. PubMed PMID: WOS:000897948100405.